Literature DB >> 19520200

Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Douglas S Watson1, Francis C Szoka.   

Abstract

The membrane proximal region (MPR) of HIV-1 gp41 is a desirable target for development of a vaccine that elicits neutralizing antibodies since the patient-derived monoclonal antibodies, 2F5 and 4E10, bind to the MPR and neutralize primary HIV isolates. The 2F5 and 4E10 antibodies cross-react with lipids and structural studies suggest that MPR immunogens may be presented in a membrane environment. We hypothesized that covalent attachment of lipid anchors would enhance the humoral immune response to MPR-derived peptides presented in liposomal bilayers. In a comparison of eight lipids conjugated to an extended 2F5 epitope peptide, a sterol, cholesterol hemisuccinate (CHEMS), was found to promote the strongest anti-peptide IgG titers (6.4 x 10(4)) in sera of BALB/C mice. Two lipid anchors, palmitic acid and phosphatidylcholine, failed to elicit a detectable serum anti-peptide IgG response. Association with the liposomal vehicle contributed to the ability of a lipopeptide to elicit anti-peptide antibodies, but no other single factor, such as position of the lipid anchor, peptide helical content, lipopeptide partition coefficient, or presence of phosphate on the anchor clearly determined lipopeptide potency. Conjugation to CHEMS also rendered a 4E10 epitope peptide immunogenic (5.6 x 10(2) IgG titer in serum). Finally, attachment of CHEMS to a peptide spanning both the 2F5 and 4E10 epitopes elicited serum IgG antibodies that bound to each of the individual epitopes as well as to recombinant gp140. Further research into the mechanism of how structure influences the immune response to the MPR may lead to immunogens that could be useful in prime-boost regimens for focusing the immune response in an HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520200      PMCID: PMC2730955          DOI: 10.1016/j.vaccine.2009.05.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  55 in total

Review 1.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

2.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

3.  HIV-1 hides an Achilles' heel in virion lipids.

Authors:  Barton F Haynes; S Munir Alam
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

4.  Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes.

Authors:  Zoltan Beck; Nicos Karasavvas; Gary R Matyas; Carl R Alving
Journal:  J Drug Target       Date:  2008-08       Impact factor: 5.121

5.  Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Authors:  S Munir Alam; Richard M Scearce; Robert J Parks; Kelly Plonk; Steven G Plonk; Laura L Sutherland; Miroslaw K Gorny; Susan Zolla-Pazner; Stacie Vanleeuwen; M Anthony Moody; Shi-Mao Xia; David C Montefiori; Georgia D Tomaras; Kent J Weinhold; Salim Abdool Karim; Charles B Hicks; Hua-Xin Liao; James Robinson; George M Shaw; Barton F Haynes
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

6.  Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.

Authors:  Nerea Huarte; Maier Lorizate; Renate Kunert; José L Nieva
Journal:  FEBS Lett       Date:  2008-10-16       Impact factor: 4.124

7.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

8.  Lipid A and liposomes containing lipid A as antigens and adjuvants.

Authors:  Carl R Alving; Mangala Rao
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

9.  Antibodies induced by liposomal protein exhibit dual binding to protein and lipid epitopes.

Authors:  Nicos Karasavvas; Zoltan Beck; James Tong; Gary R Matyas; Mangala Rao; Francine E McCutchan; Nelson L Michael; Carl R Alving
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

10.  Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.

Authors:  Adam Penn-Nicholson; Dong P Han; Soon J Kim; Hanna Park; Rais Ansari; David C Montefiori; Michael W Cho
Journal:  Virology       Date:  2007-12-19       Impact factor: 3.616

View more
  22 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

Review 3.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 4.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

5.  Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors:  Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

Review 6.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Authors:  Marie Pancera; Anita Changela; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

7.  Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.

Authors:  Vincent J Venditto; Douglas S Watson; Michael Motion; David Montefiori; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2012-10-31

8.  Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Authors:  Gary R Matyas; Alexander V Mayorov; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Malliga R Iyer; Fuying Li; Zoltan Beck; Kim D Janda; Carl R Alving
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

Review 9.  Amphipathic properties of HIV-1 gp41 fusion inhibitors.

Authors:  Miriam Gochin; Guangyan Zhou
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

10.  Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Authors:  Mikyung Kim; Likai Song; James Moon; Zhen-Yu J Sun; Anna Bershteyn; Melissa Hanson; Derek Cain; Selasie Goka; Garnett Kelsoe; Gerhard Wagner; Darrell Irvine; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.